The Efficacy and Safety of Teprotumumab in Thyroid Eye Disease: Evidence from Randomized Controlled Trials

Table 2

The results of safety in meta-analysis.

Outcomes	Participants		I ^2 (%)	Effect estimate	value
	Dorzagliatin arm	Comparator arm
Any AEs	134/168	121/172	0	1.66 [1.01, 2.73]	0.05
SAEs	14/168	3/172	0	5.12 [1.44, 18.13]	0.01
Muscle spasm	42/168	12/172	0	4.48 [2.26, 8.89]	<0.0001
Nausea	28/168	16/172	0	1.95 [1.01, 3.75]	0.05
Alopecia	22/168	14/172	0	1.71 [0.84, 3.49]	0.14
Diarrhea	20/168	14/172	0	1.52 [0.74, 3.12]	0.25
Fatigue	15/168	7/172	0	2.36 [0.93, 6.00]	0.07
Headache	14/168	12/172	0	1.21 [0.54, 2.71]	0.64
Dry skin	14/168	0/172	0	11.54 [2.13, 62.57]	0.005
Dysgeusia	14/168	0/172	0	11.54 [2.13, 62.57]	0.005